The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Soluble Type II Transforming Growth Factor-β Receptor Inhibits Established Murine Malignant Mesothelioma Tumor Growth by Augmenting Host Antitumor Immunity
Abstract
PURPOSE: Transforming growth factor (TGF)-beta blockade has been proposed as an anticancer therapy; however, understanding which tumor patients might benefit most from such therapy is crucial. An ideal target of such inhibitory therapy might be malignant mesothelioma (MM), a highly lethal, treatment-resistant malignancy of mesothelial cells of the pleura and peritoneum that produces large amounts of TGF-beta. The purpose of this study was to explore the possible therapeutic utility of TGF-beta blockade on MM. EXPERIMENTAL DESIGN: To evaluate this hypothesis, we tested the effects of a soluble TGF-beta type II receptor (sTGF-beta R) that specifically inhibits TGF-beta1 and TGF-beta 3 in three different murine MM tumor models, AB12 and AC29 (which produce large amounts of TGF-beta) and AB1 (which does not produce TGF-beta). RESULTS: Tumor growth of both established AB12 and AC29 tumors was inhibited by sTGF-beta R. In contrast, AB1 tumors showed little response to sTGF-beta R. The mechanism of these antitumor effects was evaluated and determined to be primarily dependent on immune-mediated responses because (a) the antitumor effects were markedly diminished in severe combined immunodeficient mice or mice depleted of CD8(+) T cells and (b) CD8(+) T cells isolated from spleens of mice treated with sTGF-beta R showed strong antitumor cytolytic effects, whereas CD8(+) T cells isolated from spleens of tumor-bearing mice treated with of control IgG2a showed no antitumor cytolytic effects. CONCLUSIONS: Our data suggest that TGF-beta blockade of established TGF-beta-secreting MM should be explored as a promising strategy to treat patients with MM and other tumors that produce TGF-beta.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As previously mentioned in this review, TGF-β itself and its family members have been recognized to be involved in cancer development [81], and TGF-β possesses a pro-oncogenic role in MPM connected to immune suppression [82,83].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [82]
Citations
Cites
TGF-β Signaling in Tumor Suppression and Cancer Progression
Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275
Derynck, R., Jarrett, J. A., Chen, E. Y., Eaton, D. H., Bell, J. R., Assoian, R. K., Roberts, A. B., Sporn, M. B., & Goeddel, D. V. (1985) · Nature · doi:10.1038/316701a0 · Cited by 1,667
Transforming Growth Factor-β: Biological Function and Chemical Structure
Sporn, M. B., Roberts, A. B., Wakefield, L. M., & Assoian, R. K. (1986) · Science · doi:10.1126/science.3487831 · Cited by 1,182
Transforming growth factor-β in T-cell biology
Gorelik, L., & Flavell, R. A. (2002) · Nature Reviews Immunology · doi:10.1038/nri704 · Cited by 792
Gorelik, L., & Flavell, R. A. (2001) · Nature Medicine · doi:10.1038/nm1001-1118 · Cited by 770
Abe, M., Harpel, J. G., Metz, C. N., Nunes, I., Loskutoff, D. J., & Rifkin, D. B. (1994) · Analytical Biochemistry · doi:10.1006/abio.1994.1042 · Cited by 757
The TGF-β family of growth and differentiation factors
Massagué, J. (1987) · Cell · doi:10.1016/0092-8674(87)90443-0 · Cited by 664
Van Obberghen-Schilling, E., Roche, N. S., Flanders, K. C., Sporn, M. B., & Roberts, A. B. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)68561-8 · Cited by 601
Ranges, G. E., Figari, I. S., Espevik, T., & Palladino, M. A. (1987) · The Journal of experimental medicine · doi:10.1084/jem.166.4.991 · Cited by 494
Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.
Nowak, A. K., Robinson, B. W. S., & Lake, R. (2003) · PubMed · Cited by 421
Research works printed but not linked: 1
- Kumar-Singh S, Weyler J, Martin MJH, Vermeulen PB, Van Marck E. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TFGβ expression. J Pathol, 189: 72-8, 1999. · doi:10.1002/(sici)1096-9896(199909)189:1<72::aid-path401>3.0.co;2-0
Cited by
Adoptive T cell therapy for cancer in the clinic
June, C. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32446 · Cited by 553
Transforming growth factor-β: a therapeutic target for cancer
Haque, S., & Morris, J. C. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1327107 · Cited by 276
Nam, J.-S., Terabe, M., Kang, M.-J., Chae, H., Voong, N., Yang, Y.-A., Laurence, A., Michalowska, A., Mamura, M., Lonning, S., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0206 · Cited by 251
Targeting TGF-β Signaling for Therapeutic Gain
Akhurst, R. J. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a022301 · Cited by 241
Nam, J.-S., Terabe, M., Mamura, M., Kang, M.-J., Chae, H., Stuelten, C., Kohn, E., Tang, B., Sabzevari, H., Anver, M. R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0215 · Cited by 233
Metadata
- Authors
- Suzuki, E., Kapoor, V., Cheung, H.-K., Ling, L. E., DeLong, P. A., Kaiser, L. R., & Albelda, S. M.
- Affiliations
- University of Pennsylvania (US)
- Biogen (United States) (US)
- 1Thoracic Oncology Research Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania; and
- Venue
- Clinical Cancer Research
- Published
- 2004-09-01
- Volume
- 10
- Issue
- 17
- Pages
- 5907-5918
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2023961961
- Cited by
- 65
- References
- 59
- Citations by year
- 2024: 1 · 2023: 1 · 2021: 1 · 2019: 2 · 2018: 2 · 2017: 4 · 2016: 1 · 2015: 2 · 2014: 2 · 2013: 5 · 2012: 7
- FWCI
- 2.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (P01 66726)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- malignant mesothelioma, TGF-beta blockade, antitumor immunity, CD8+ T cells, tumor growth inhibition, TGF-β1, TGF-beta3, SCID mice, tumor immunology
- MeSH terms
- Receptor, Transforming Growth Factor-beta Type II, Animals, Female, Genes, MHC Class II, Genes, MHC Class I, Lymphocyte Depletion, Mesothelioma, Mice, Inbred BALB C, Mice, Inbred CBA, Spleen, T-Lymphocytes, Cytotoxic, Tumor Cells, Cultured, CD4-Positive T-Lymphocytes, Transforming Growth Factor beta, Mice, SCID, Protein Serine-Threonine Kinases, Receptors, Transforming Growth Factor beta, CD8-Positive T-Lymphocytes, fas Receptor, Mice, Transforming Growth Factor beta1, Transforming Growth Factor beta3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Soluble Type II Transforming Growth Factor-β Receptor Inhibits Established Murine Malignant Mesothelioma Tumor Growth by Augmenting Host Antitumor Immunity. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-03-0611
- The paper
- Suzuki, E., Kapoor, V., Cheung, H.-K., Ling, L. E., DeLong, P. A., Kaiser, L. R., & Albelda, S. M. (2004). Soluble Type II Transforming Growth Factor-β Receptor Inhibits Established Murine Malignant Mesothelioma Tumor Growth by Augmenting Host Antitumor Immunity. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-03-0611
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.